{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:38:50Z","timestamp":1788514730409,"version":"build-2803163510"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory condition affecting the nasal passages and paranasal sinuses. It is characterized by persistent inflammation and often leads to a considerable decline in health-related quality of life (HRQoL). A subset of these patients\u2014approximately 17.7%\u2014have NSAID-exacerbated respiratory disease (N-ERD), a more severe form that frequently necessitates repeated sinus surgeries and rescue therapies. Compared with individuals without N-ERD, affected patients are more prone to asthma flare-ups, severe hypersensitivity reactions, and loss of smell. Treatment with acetylsalicylic acid (ASA) following desensitization (ATAD) has been suggested as a therapeutic option in cases of severe CRSwNP with N-ERD. While this approach may offer symptom improvement, decreased polyp burden, and enhanced QoL, it is not without risks, such as gastrointestinal irritation and bleeding complications. This randomized, double-blind, placebo-controlled clinical trial (RDBCT) assesses the effectiveness and safety of ATAD in comparison with placebo in patients suffering from severe CRSwNP, N-ERD, and asthma. The study explores various outcomes, including reduction in polyp burden, improvement in QoL, treatment-related side effects, and biomarker analyses derived from nasal swabs, blood, and urine samples.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>AirGOs Medical is an investigator-initiated RDBCT conducted at Helsinki University Hospital. Participants are randomized to receive either ATAD or placebo. The primary endpoint is the change in the SNOT-22 score observed at the 11-month follow-up. Secondary measures include variations in nasal polyp scores, CRS symptom control, general HRQoL, work productivity loss, peak nasal inspiratory flow (PNIF) with or without acoustic rhinometry (ARM), olfactory function assessed by the Sniffin' Sticks identification test, spirometry, peak expiratory flow (PEF), and histopathological findings at the 12-month follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The AirGOs Medical trial is expected to generate data on the therapeutic value and safety profile of ATAD in patients with coexisting severe CRSwNP, N-ERD, and asthma, potentially informing future clinical practice.\n<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>[<jats:uri>ClinicalTrials.gov<\/jats:uri>], identifier [NCT03825757]. Registered on 28.2.2019.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2025.1542481","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:12:51Z","timestamp":1747735971000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Study protocol for a randomized double-blinded placebo-controlled trial on ASA therapy for patients with chronic rhinosinusitis with nasal polyps, NSAID-exacerbated respiratory disease, and asthma"],"prefix":"10.3389","volume":"6","author":[{"given":"Sanna","family":"Toppila-Salmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annina","family":"Lyly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viljami","family":"Salmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Nuutinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kilpi\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanzeela","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Niemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Laulajainen-Hongisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Hafr\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"M\u00e4kel\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Kauppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Virkkula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Helev\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/j.1398-9995.2011.02646.x","article-title":"Chronic rhinosinusitis in Europe\u2014an underestimated disease. A GA 2LEN study","volume":"66","author":"Hastan","year":"2011","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jaci.2018.12.986","article-title":"Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology","volume":"143","author":"Dietz de Loos","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"29","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4193\/Rhin19.468","article-title":"Direct and indirect costs of adult patients with chronic rhinosinusitis with nasal polyps","volume":"58","author":"Lourijsen","year":"2020","journal-title":"Rhinology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.alit.2019.05.001","article-title":"Aspirin-exacerbated respiratory disease (AERD): current understanding of AERD","volume":"68","author":"Taniguchi","year":"2019","journal-title":"Allergol Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/all.13599","article-title":"Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)-a EAACI position paper","volume":"74","author":"Kowalski","year":"2019","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.3389\/fphar.2020.01147","article-title":"NSAID-exacerbated respiratory disease (NERD): from pathogenesis to improved care","volume":"11","author":"Woo","year":"2020","journal-title":"Front Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.12932\/AP-310321-1102","article-title":"Eosinophilia, asthma, NERD and the use of oral corticosteroids predict uncontrolled chronic rhinosinusitis with nasal polyps after surgery","volume":"42","author":"Penttil\u00e4","year":"2024","journal-title":"Asian Pac J Allergy Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e12181","DOI":"10.1002\/clt2.12181","article-title":"The relative proportion of comorbidities among rhinitis and rhinosinusitis patients and their impact on visit burden","volume":"12","author":"Nuutinen","year":"2022","journal-title":"Clin Transl Allergy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0091-6749(99)70106-5","article-title":"Aspirin-induced asthma: advances in pathogenesis and management","volume":"104","author":"Szczeklik","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/ACI.0000000000000374","article-title":"Aspirin challenge and desensitization: how, when and why","volume":"17","author":"Cortellini","year":"2017","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0091-6749(82)90081-1","article-title":"Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period","volume":"69","author":"Pleskow","year":"1982","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.iac.2012.10.013","article-title":"Aspirin desensitization in aspirin-exacerbated respiratory disease","volume":"33","author":"White","year":"2013","journal-title":"Immunol Allergy Clin North Am"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/alr.22428","article-title":"Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis","volume":"9","author":"Chu","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"638136","DOI":"10.3389\/falgy.2021.638136","article-title":"The nose as a route for therapy: part 1. Pharmacotherapy","volume":"2","author":"Cingi","year":"2021","journal-title":"Front Allergy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0091-6749(98)70163-0","article-title":"Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma","volume":"101","author":"Milewski","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhino12.000","article-title":"EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists","volume":"50","author":"Fokkens","year":"2012","journal-title":"Rhinology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jaci.2020.10.043","article-title":"The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: a work group report from the rhinitis, rhinosinusitis and ocular allergy committee of the American Academy of Allergy, Asthma and Immunology","volume":"147","author":"Stevens","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1016\/j.jaip.2020.06.063","article-title":"High discontinuation rates of peroral ASA treatment for CRSwNP: a real-world multicenter study of 171 N-ERD patients","volume":"8","author":"Laulajainen-Hongisto","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item sinonasal outcome test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00405-020-06297-w","article-title":"Translation, cross-cultural adaptation, and validation of the sino-nasal outcome test (snot)-22 for Finnish patients","volume":"278","author":"Koskinen","year":"2021","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/coa.13177","article-title":"Minimal clinically important difference for the 22-item sinonasal outcome test in medically managed patients with chronic rhinosinusitis","volume":"43","author":"Phillips","year":"2018","journal-title":"Clin Otolaryngol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11136-020-02688-y","article-title":"Psychometric properties of the EQ-5D-5l: a systematic review of the literature","volume":"30","author":"Feng","year":"2021","journal-title":"Qual Life Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3109\/07853890109002086","article-title":"The 15D instrument of health-related quality of life: properties and applications","volume":"33","author":"Sintonen","year":"2001","journal-title":"Ann Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11136-014-0787-4","article-title":"Estimating the minimum important change in the 15D scores","volume":"24","author":"Alanne","year":"2015","journal-title":"Qual Life Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1007\/s00405-023-07872-7","article-title":"Self-assessment of olfactory function using the \u201cSniffin\u2019 Sticks\u201d","volume":"280","author":"Mai","year":"2023","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4193\/Rhino10.097","article-title":"Minimal clinically important differences in nasal peak inspiratory flow","volume":"49","author":"Timperley","year":"2011","journal-title":"Rhinol J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"190137","DOI":"10.1183\/16000617.0137-2019","article-title":"Minimal clinically important difference for asthma endpoints: an expert consensus report","volume":"29","author":"Bonini","year":"2020","journal-title":"Eur Respir Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1553-2712.2000.tb02231.x","article-title":"Clinically meaningful changes in quantitative measures of asthma severity","volume":"7","author":"Karras","year":"2000","journal-title":"Acad Emerg Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"B32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/000348949510410s02","article-title":"Quantification for staging sinusitis. The staging and therapy group","volume":"167","author":"Lund","year":"1995","journal-title":"Ann Otol Rhinol Laryngol Suppl"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1002\/lary.24654","article-title":"Modification of the Lund-Kennedy endoscopic scoring system improves its reliability and correlation with patient-reported outcome measures","volume":"124","author":"Psaltis","year":"2014","journal-title":"Laryngoscope"},{"key":"B34","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/all.15650","article-title":"European academy of allergy and clinical immunology position paper on endoscopic scoring of nasal polyposis","volume":"78","author":"Gevaert","year":"2023","journal-title":"Allergy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/all.12040","article-title":"Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today?","volume":"68","author":"Hellings","year":"2013","journal-title":"Allergy"},{"key":"B37","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jaci.2006.01.011","article-title":"Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists","volume":"117","author":"Schatz","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1034\/j.1399-3003.1999.14a08.x","article-title":"Development and validation of the mini asthma quality of life questionnaire","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur Respir J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0895-4356(94)90036-1","article-title":"Determining a minimal important change in a disease-specific quality of life questionnaire","volume":"47","author":"Juniper","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the asthma control test","volume":"124","author":"Schatz","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar3141","article-title":"Validity of the work productivity and activity impairment questionnaire\u2014general health version in patients with rheumatoid arthritis","volume":"12","author":"Zhang","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"A550","DOI":"10.1016\/j.jval.2014.08.1791","article-title":"IMTA productivity cost questionnaire (IPCQ)","volume":"17","author":"Bouwmans","year":"2014","journal-title":"Value Health"},{"key":"B43","first-page":"1639","article-title":"Clinical and immunological efficacy of aspirin desensitization in nasal polyp patients with aspirin-exacerbated respiratory disease","volume":"16","author":"Mortazavi","year":"2017","journal-title":"Iran J Pharm Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.clim.2015.05.012","article-title":"Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: a randomized double-blind placebo-controlled trial","volume":"160","author":"Esmaeilzadeh","year":"2015","journal-title":"Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jaci.2014.02.041","article-title":"Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study","volume":"134","author":"\u015awierczy\u0144ska-Kr\u0119pa","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/all.12131","article-title":"Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease","volume":"68","author":"Fruth","year":"2013","journal-title":"Allergy"},{"key":"B47","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/0091-6749(84)90361-0","article-title":"Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin","volume":"73","author":"Stevenson","year":"1984","journal-title":"J Allergy Clin Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jaci.2021.06.019","article-title":"Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1016\/j.jaip.2024.09.012","article-title":"Current goals of NSAID-ERD management: patient-centered approaches involving NSAID desensitization with and without biologics","volume":"12","author":"Bobolea","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.jaip.2021.12.030","article-title":"Controversies in allergy: aspirin desensitization or biologics for aspirin-exacerbated respiratory disease\u2014how to choose","volume":"10","author":"Laidlaw","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1080951","DOI":"10.3389\/falgy.2023.1080951","article-title":"Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?","volume":"4","author":"Van Broeck","year":"2023","journal-title":"Front Allergy"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1542481\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:12:52Z","timestamp":1747735972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1542481\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":51,"alternative-id":["10.3389\/falgy.2025.1542481"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1542481","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"article-number":"1542481"}}